Q3192980 (Q3192980): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item: Edited by the materialized bot - inferring region from the coordinates) |
(Created claim: summary (P836): The overall objective of the project is to generate knowledge, technologies and develop solutions applicable to the food industry by providing more effective, safer and targeted food and ingredients for an increasingly prevalent population such as people with inflammation-related health problems, analysing the relationship between the microbiome and the underlying inflammatory processes. Our hypothesis is that both genomic variants and microbiom...) |
||||||||||||||
| Property / summary | |||||||||||||||
The overall objective of the project is to generate knowledge, technologies and develop solutions applicable to the food industry by providing more effective, safer and targeted food and ingredients for an increasingly prevalent population such as people with inflammation-related health problems, analysing the relationship between the microbiome and the underlying inflammatory processes. Our hypothesis is that both genomic variants and microbiome form part of the integrative basis of pathogenesis with an inflammatory source and maintenance of lesions. The results obtained in this study will serve as a basis for the development of biological approaches capable of reversing the inflammatory process. The results obtained from this study will allow to focus new studies on the role of bacteria in inflammation through the modulation of the microbiota. To achieve this objective, the project intends to address all aspects related to this issue, i.e. from the perspective of industrial research. Thus, PROBIOMI is structured into three activities covering research and development tasks. Research activities focus on the selection and rational improvement of probiotic microorganisms, obtaining new probiotics, or improved probiotics, with anti-inflammatory or replacement potential for dysbiotic bacteria. Development activities are focused on analysis of selected probiotic growth capacity, probiotic resistance analysis to the lyophilisation process at laboratory level and pilot scale. PROBIOMI therefore faces a significant scientific and technological challenge and aims, in a strategic way between the company Biopolis and the research organisation I2SysBio: new probiotics for the regeneration of the diversity of the intestinal microbiota. (English) | |||||||||||||||
| Property / summary: The overall objective of the project is to generate knowledge, technologies and develop solutions applicable to the food industry by providing more effective, safer and targeted food and ingredients for an increasingly prevalent population such as people with inflammation-related health problems, analysing the relationship between the microbiome and the underlying inflammatory processes. Our hypothesis is that both genomic variants and microbiome form part of the integrative basis of pathogenesis with an inflammatory source and maintenance of lesions. The results obtained in this study will serve as a basis for the development of biological approaches capable of reversing the inflammatory process. The results obtained from this study will allow to focus new studies on the role of bacteria in inflammation through the modulation of the microbiota. To achieve this objective, the project intends to address all aspects related to this issue, i.e. from the perspective of industrial research. Thus, PROBIOMI is structured into three activities covering research and development tasks. Research activities focus on the selection and rational improvement of probiotic microorganisms, obtaining new probiotics, or improved probiotics, with anti-inflammatory or replacement potential for dysbiotic bacteria. Development activities are focused on analysis of selected probiotic growth capacity, probiotic resistance analysis to the lyophilisation process at laboratory level and pilot scale. PROBIOMI therefore faces a significant scientific and technological challenge and aims, in a strategic way between the company Biopolis and the research organisation I2SysBio: new probiotics for the regeneration of the diversity of the intestinal microbiota. (English) / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / summary: The overall objective of the project is to generate knowledge, technologies and develop solutions applicable to the food industry by providing more effective, safer and targeted food and ingredients for an increasingly prevalent population such as people with inflammation-related health problems, analysing the relationship between the microbiome and the underlying inflammatory processes. Our hypothesis is that both genomic variants and microbiome form part of the integrative basis of pathogenesis with an inflammatory source and maintenance of lesions. The results obtained in this study will serve as a basis for the development of biological approaches capable of reversing the inflammatory process. The results obtained from this study will allow to focus new studies on the role of bacteria in inflammation through the modulation of the microbiota. To achieve this objective, the project intends to address all aspects related to this issue, i.e. from the perspective of industrial research. Thus, PROBIOMI is structured into three activities covering research and development tasks. Research activities focus on the selection and rational improvement of probiotic microorganisms, obtaining new probiotics, or improved probiotics, with anti-inflammatory or replacement potential for dysbiotic bacteria. Development activities are focused on analysis of selected probiotic growth capacity, probiotic resistance analysis to the lyophilisation process at laboratory level and pilot scale. PROBIOMI therefore faces a significant scientific and technological challenge and aims, in a strategic way between the company Biopolis and the research organisation I2SysBio: new probiotics for the regeneration of the diversity of the intestinal microbiota. (English) / qualifier | |||||||||||||||
point in time: 12 October 2021
| |||||||||||||||
Revision as of 21:58, 12 October 2021
Project Q3192980 in Spain
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | No label defined |
Project Q3192980 in Spain |
Statements
317,068.5 Euro
0 references
634,137.0 Euro
0 references
50.0 percent
0 references
1 August 2019
0 references
1 August 2022
0 references
BIOPOLIS SL
0 references
39°30'14.11"N, 0°26'31.56"W
0 references
46190
0 references
El objetivo general del proyecto es generar conocimiento, tecnologías y desarrollar soluciones aplicables al sector industrial alimentario proporcionando ingredientes y alimentos más eficaces, más seguros y dirigidos a una población cada vez más prevalente como es el de las personas con problemas de salud relacionados con inflamación, analizar la relación entre el microbioma y los procesos inflamatorios subyacentes. Nuestra hipótesis es que tanto las variantes genómicas como el microbioma forman parte de la base integrativa de las patogénesis con fuente inflamatoria y mantenimiento de las lesiones. Los resultados obtenidos en este estudio servirán como base para el desarrollo de aproximaciones biológicas capaces de revertir el proceso inflamatorio. Los resultados que de este estudio se obtengan permitirán focalizar nuevos estudios sobre el papel de las bacterias en la inflamación a través de la modulación del microbiota. Para conseguir dicho objetivo, el proyecto se plantea con la intención de abordar todos los aspectos relacionados con esta temática, esto es, desde la perspectiva de la investigación industrial. Así, PROBIOMI se estructura en tres actividades que cubren tareas de investigación y desarrollo. Las actividades de investigación se centran en la selección y la mejora racional de los microorganismos probióticos, obtención nuevos probióticos, o probióticos mejorados, con potencial anti-inflamatorio y/o de reemplazo de bacterias disbióticas. Las actividades de desarrollo están centradas en tareas de análisis de la capacidad de crecimiento de probióticos seleccionados, análisis de resistencia de probiótico al proceso de liofilización a escala de laboratorio y escala piloto. PROBIOMI se enfrenta pues a un reto científico y tecnológico significativo y pretende, de forma estratégica entre la empresa Biopolis y el organismo de investigación I2SysBio: nuevos probióticos para la regeneración de la diversidad de la microbiota intestinal. (Spanish)
0 references
The overall objective of the project is to generate knowledge, technologies and develop solutions applicable to the food industry by providing more effective, safer and targeted food and ingredients for an increasingly prevalent population such as people with inflammation-related health problems, analysing the relationship between the microbiome and the underlying inflammatory processes. Our hypothesis is that both genomic variants and microbiome form part of the integrative basis of pathogenesis with an inflammatory source and maintenance of lesions. The results obtained in this study will serve as a basis for the development of biological approaches capable of reversing the inflammatory process. The results obtained from this study will allow to focus new studies on the role of bacteria in inflammation through the modulation of the microbiota. To achieve this objective, the project intends to address all aspects related to this issue, i.e. from the perspective of industrial research. Thus, PROBIOMI is structured into three activities covering research and development tasks. Research activities focus on the selection and rational improvement of probiotic microorganisms, obtaining new probiotics, or improved probiotics, with anti-inflammatory or replacement potential for dysbiotic bacteria. Development activities are focused on analysis of selected probiotic growth capacity, probiotic resistance analysis to the lyophilisation process at laboratory level and pilot scale. PROBIOMI therefore faces a significant scientific and technological challenge and aims, in a strategic way between the company Biopolis and the research organisation I2SysBio: new probiotics for the regeneration of the diversity of the intestinal microbiota. (English)
12 October 2021
0 references
Paterna
0 references
Identifiers
IDI-20191093
0 references